Adicet Bio Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Adicet Bio Inc.
- Former names
- resTORbio, Inc.
- Ownership
- Public
- Status
- Active
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Boston
- Headquarters state / province
- Massachusetts
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- ACET
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001720580
- EIN
- 81-3305277
Board of directors
-
Andrew Sinclair · DirectorSince 2023
-
Aya Jakobovits · DirectorSince 2023
-
Bastiano Sanna · DirectorSince 2023
- Since 2023
-
Chen Schor · Director · President & CEOSince 2023
-
Erez Chimovits · DirectorSince 2023
-
Jeffrey Chodakewitz · DirectorSince 2023
-
Katie Peng · DirectorSince 2023
-
Lloyd Klickstein · Director · Chief Medical OfficerSince 2024
-
Michael Grissinger · DirectorSince 2025
-
Michael Kauffman · DirectorSince 2023
-
Steve Dubin · DirectorSince 2023
Chief executives
Chen Schor
· President & CEO
Dates unknown
Director election results
Annual meeting of June 17, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
85.7%
-
86.4%
-
98.0%
Board connections
7 of this board's directors also sit on 18 other boards.
- via Michael Grissinger
- via Michael Grissinger
- via Carl L. Gordon
- via Carl L. Gordon
- via Erez Chimovits
- via Carl L. Gordon
- via Carl L. Gordon
- via Chen Schor
- via Carl L. Gordon
- via Michael Kauffman
- via Michael Grissinger
- via Carl L. Gordon
- via Jeffrey Chodakewitz
- via Katie Peng
- via Jeffrey Chodakewitz
- via Carl L. Gordon
- via Erez Chimovits
- via Michael Kauffman
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $6,603,934
- 5 purchases by 2 insiders
- Sold, last 12 months
- $674,847
- 4 sales by 1 insider
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Apr 27, 2026 | Rajeev M. Shah 10% owner | Other | −250,000 | — | — |
| Apr 8, 2026 | OrbiMed Advisors Israel II Ltd 10% owner | Open-market sale | −32,523 | $6.29 | $204,570 |
| Apr 8, 2026 | OrbiMed Advisors Israel II Ltd 10% owner | Open-market sale | −40,416 | $6.52 | $263,512 |
| Apr 7, 2026 | OrbiMed Advisors Israel II Ltd 10% owner | Open-market sale | −29,319 | $6.53 | $191,453 |
| Apr 7, 2026 | OrbiMed Advisors Israel II Ltd 10% owner | Open-market sale | −2,400 | $6.38 | $15,312 |
| Feb 20, 2026 | RA Capital Healthcare Fund LP 10% owner | Open-market purchase | +74,751 | $7.27 | $543,440 |
| Feb 19, 2026 | RA Capital Healthcare Fund LP 10% owner | Open-market purchase | +74,268 | $7.21 | $535,472 |
| Feb 18, 2026 | RA Capital Healthcare Fund LP 10% owner | Open-market purchase | +74,577 | $7.04 | $525,022 |
| Jan 24, 2026 | Aftab Blake Officer (Chief Scientific Officer) | Shares withheld for tax | −535 | $8.44 | $4,515 |
| Jan 24, 2026 | Healey Don Officer (Chief Technology Officer) | Shares withheld for tax | −535 | $8.44 | $4,515 |
| Jan 24, 2026 | Chen Schor Director, Officer (President & CEO) | Shares withheld for tax | −1,755 | $8.44 | $14,812 |
| Jan 24, 2026 | Harvey Brian Nicholas Officer (Chief Financial Officer) | Shares withheld for tax | −546 | $8.44 | $4,608 |
| Oct 8, 2025 | ORBIMED ADVISORS LLC 10% owner | Open-market purchase | +1,500,000 | $1.00 | $1,500,000 |
| Oct 8, 2025 | ORBIMED ADVISORS LLC 10% owner | Open-market purchase | +3,500,000 | $1.00 | $3,500,000 |
| Jun 11, 2025 | Lloyd Klickstein Director | Grant or award | +5,900 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.